Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL779852 | 0.86 | NPC1 (0.54) | KMT2ACYP1A2CYP3A4CYP2C19PDK1 | |
| SCHEMBL778394 | 0.81 | KMT2A (0.63) | KMT2ACYP1A2CYP3A4CYP2C19PDK1 | |
| SCHEMBL1748243 | 0.81 | KMT2A (1.00) | KMT2ACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL27917560 | 0.81 | APP (0.74) | NPC1RAB9ASMN1; SMN2APPGAA | |
| SCHEMBL299010 | 0.80 | CYP1A2 (0.67) | KMT2ACYP1A2CYP3A4CYP2C19PDK1 | |
| SCHEMBL422166 | 0.80 | CYP1A2 (0.67) | KMT2ACYP1A2CYP3A4CYP2C19PDK1 | |
| SCHEMBL10531693 | 0.79 | CA2 (0.63) | KMT2ACYP1A2CYP3A4CYP2C19NPC1 | |
| SCHEMBL30189879 | 0.79 | KMT2A (0.60) | KMT2ACYP1A2CYP3A4CYP2C19PDK1 | |
| SCHEMBL1748095 | 0.79 | KMT2A (0.78) | KMT2ACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL19783157 | 0.79 | KMT2A (0.60) | KMT2ACYP1A2CYP3A4CYP2C19PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109485620-A | A kind of preparation method of 2- methoxyl group -6- methoxybenzothiazole | 安徽工大化工科技有限公司 | 2019-03-19 | — | — | CN | claimed |
| CN-109456281-A | A kind of preparation method of the chloro- 6- methoxybenzothiazole of 2- | 安徽工大化工科技有限公司 | 2019-03-12 | — | — | CN | claimed |
| US-4826989-A | Process for the preparation of luciferin compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1989-05-02 | — | — | US | claimed |
| EP-0024525-B1 | Process for the preparation of luciferin and its derivatives | Roche Diagnostics GmbH (DE) | 1982-06-30 | — | — | EP | claimed |
| EP-0024525-A1 | Process for the preparation of luciferin and its derivatives | Roche Diagnostics GmbH (DE) | 1981-03-11 | — | — | EP | claimed |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| CN-117120423-B | Indolylamine 2, 3-dioxygenase inhibitors, methods of preparing the same, and pharmaceutical compositions containing the same | 柳韩洋行 | 2026-02-27 | — | — | CN | disclosed |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| US-20250011293-A1 | LEUKOTRIENE SYNTHESIS INHIBITORS | NAEGIS PHARMACEUTICALS INC. (CA) | 2025-01-09 | — | — | US | disclosed |
| US-12162871-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-09-19 | — | — | US | disclosed |
| EP-0742010-A2 | Benzoquinolin-3-ones to inhibit bone loss | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0733365-A2 | Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5550134-A | ADMINISTERING TO A MAMMAL FROM A SERIES OF BENZOQUINOLIN-3-ONE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| US-4873346-A | BRONCHODILATORS, TREATMENT OF ASTHMA | THE UPJOHN COMPANY (US) | 1989-10-10 | — | — | US | disclosed |
| US-4826989-A | Process for the preparation of luciferin compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1989-05-02 | — | — | US | disclosed |
| EP-0123087-A1 | Process for the preparation of heterocyclic phenyl ether | CASSELLA Aktiengesellschaft (DE) | 1984-10-31 | — | — | EP | disclosed |
| EP-0024525-B1 | Process for the preparation of luciferin and its derivatives | Roche Diagnostics GmbH (DE) | 1982-06-30 | — | — | EP | disclosed |
| EP-0024525-A1 | Process for the preparation of luciferin and its derivatives | Roche Diagnostics GmbH (DE) | 1981-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162871-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | KMT2A 4170/4885CYP1A2 4278/4885CYP3A4 4363/4885 |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, F2R | KMT2A 897/4885CYP1A2 134/4885CYP3A4 24/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | KMT2A 1722/4885CYP1A2 2758/4885CYP3A4 2368/4885 |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | KMT2A 2239/4885CYP1A2 3089/4885CYP3A4 2504/4885 |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, F2R, PF4 | KMT2A 2733/4885CYP1A2 103/4885CYP3A4 23/4885 |
| US-20250011293-A1 | LEUKOTRIENE SYNTHESIS INHIBITORS | LTC4S, LTB4R2, LTA4H | KMT2A 4046/4885CYP1A2 502/4885CYP3A4 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.